ID   LoVo_6244R
AC   CVCL_C3GL
SY   L6244-R
DR   cancercelllines; CVCL_C3GL
DR   GEO; GSM3591766
DR   Wikidata; Q114311891
RX   PubMed=31048689;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244).
CC   Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0399 ! LoVo
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=31048689; DOI=10.1038/s41467-019-09438-w;
RA   Sale M.J., Balmanno K., Saxena J., Ozono E., Wojdyla K.,
RA   McIntyre R.E., Gilley R., Woroniuk A., Howarth K.D., Hughes G.,
RA   Dry J.R., Arends M.J., Caro P., Oxley D., Ashton S., Adams D.J.,
RA   Saez-Rodriguez J., Smith P.D., Cook S.J.;
RT   "MEK1/2 inhibitor withdrawal reverses acquired resistance driven by
RT   BRAF(V600E) amplification whereas KRAS(G13D) amplification promotes
RT   EMT-chemoresistance.";
RL   Nat. Commun. 10:2030.1-2030.22(2019).
//